Celgene Corporation (CELG) Position Cut by B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund trimmed its stake in Celgene Corporation (NASDAQ:CELG) by 7.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,625 shares of the biopharmaceutical company’s stock after selling 1,756 shares during the quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Celgene Corporation were worth $2,691,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in CELG. Flagship Harbor Advisors LLC lifted its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares in the last quarter. Baker Avenue Asset Management LP lifted its position in Celgene Corporation by 4.8% during the first quarter. Baker Avenue Asset Management LP now owns 13,201 shares of the biopharmaceutical company’s stock valued at $1,643,000 after buying an additional 601 shares in the last quarter. Teewinot Capital Advisers L.L.C. lifted its position in Celgene Corporation by 19.9% during the first quarter. Teewinot Capital Advisers L.L.C. now owns 82,208 shares of the biopharmaceutical company’s stock valued at $10,229,000 after buying an additional 13,625 shares in the last quarter. Endurant Capital Management LP lifted its position in Celgene Corporation by 62.1% during the first quarter. Endurant Capital Management LP now owns 57,500 shares of the biopharmaceutical company’s stock valued at $7,155,000 after buying an additional 22,020 shares in the last quarter. Finally, Shelton Capital Management lifted its position in Celgene Corporation by 18.3% during the first quarter. Shelton Capital Management now owns 106,482 shares of the biopharmaceutical company’s stock valued at $13,250,000 after buying an additional 16,488 shares in the last quarter. Hedge funds and other institutional investors own 79.43% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.13% during trading on Tuesday, reaching $141.11. 846,934 shares of the company were exchanged. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.64. The stock has a market capitalization of $110.40 billion, a P/E ratio of 43.70 and a beta of 1.89. The stock has a 50-day moving average of $134.21 and a 200 day moving average of $126.84.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the company posted $1.44 earnings per share. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

In related news, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 263,011 shares of company stock valued at $35,078,473. 0.95% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Celgene Corporation (CELG) Position Cut by B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/09/12/celgene-corporation-celg-position-cut-by-b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund.html.

A number of research analysts have weighed in on CELG shares. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price target on the stock. in a research report on Tuesday, August 29th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research reaffirmed a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research report on Wednesday, May 24th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their price target for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty-two have assigned a buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and a consensus target price of $147.31.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply